Pharm-Olam International Expands Data Management and Biostatistic Services

HOUSTON, TEXAS Sept 27, 2006. Pharm-Olam International Ltd. (POI), a multi-national CRO to pharmaceutical, biotechnology and medical device industries, announces continued expansion of their data management and biostatistics services which includes the addition of new senior management positions.

Dr. Anthony Orlando, Ph.D. joins Pharm-Olam in the new position of Vice President, Global Data Division which oversees the company's data management and biostatistics services. Dr. Orlando brings an exceptional background in data management and biostatistics with over 30 years of experience which includes roles in pharmaceutical companies, the National Center for Toxicological Research/FDA, and contract research organizations. Dr. Orlando holds a Ph.D. in Biometry from Yale University, and has co-authored many papers in his area of expertise and has supported several drug NDAs for a variety of indications.

Louise Pitcher was appointed Associate Director of Clinical Data Management. She has worked as a Data Manager and Project Manager for the last 10 years for Pharmaceutical companies and a CRO before moving to Pharm-Olam. Louise has over 6 years experience of Electronic Data Capture technology, its system integration, process improvements and training. She joins us from Procter & Gamble Inc. where she managed many pivotal clinical trials, Phases I - III in various therapeutic areas.

Pharm-Olam's data management system uses a secure, web-based platform that is 21 CFR 11 compliant. Pharm-Olam's provides sponsors with flexible options for EDC which includes direct data entry by the site and the option of local electronic data entry (LEDE). LEDE uses a hybrid model which combines paper CRFs and locally performed EDC that provides the sponsor with several advantages over traditional paper processes.

For further information about Pharm-Olam please contact Iain Gordon at igordon@pharm-olam.com.


About Pharm-Olam International

Pharm-Olam International is a multi-national contract research organization offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From pre-clinical to Phase IV, POI focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines.